Axa’s Pacira BioSciences PCRX Stock Holding History

Axa’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-117,285	Closed	-$2.8M	–	772
2025 Q2	$2.8M	Hold	117,285	–	–	0.01%	698
2025 Q1	$2.91M	Buy	117,285 +27,803	+31%	+$666K	0.01%	656
2024 Q4	$1.69M	Buy	+89,482	New	+$1.57M	0.01%	787

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Axa's PCRX Position: Q3 2025 in Review

Axa sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 117,285 shares — an estimated $2.8M sold.

Axa first reported a position in PCRX in Q4 2024 and held it in 3 quarters. The position peaked at $2.91M in Q1 2025. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

Axa reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
Axa sold 117,285 Pacira BioSciences shares in Q3 2025, an estimated $2.8M.
Axa first reported a position in Pacira BioSciences in Q4 2024 and held it in 3 quarters.
Axa's Pacira BioSciences position peaked at $2.91M in Q1 2025.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.